Literature DB >> 7114591

Failure of peak expiratory flow rate to predict hospital admission in acute asthma.

T G Martin, R M Elenbaas, S H Pingleton.   

Abstract

Our study evaluated the ability of early peak expiratory flow rates (PEFR) to be predictive of hospital admission while double blinding the measurements and using a standardized treatment protocol and specific admission criteria. The measurements were recorded prior to and after initial therapy. Eighty-six acute asthmatic episodes in 51 patients were analyzed. Nine (10.5%) of the episodes resulted in hospitalization; 77 (89.5%) resulted in discharge. No correlation with admission was found for the initial PEFR, a second PEFR following treatment, or the differences between these two values. Our study indicates that early PEFRs alone are not useful predictors of the need for hospital admission. Although a significant number of patients in our study population presented with severe airflow obstruction, they responded sufficiently to treatment to permit discharge.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7114591     DOI: 10.1016/s0196-0644(82)80063-2

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  4 in total

Review 1.  Status asthmaticus. From the emergency department to the intensive care unit.

Authors:  N Kenyon; T E Albertson
Journal:  Clin Rev Allergy Immunol       Date:  2001-06       Impact factor: 8.667

2.  The value of pulmonary function tests in the management of acute asthma.

Authors:  J R Worthington; J Ahuja
Journal:  CMAJ       Date:  1989-01-15       Impact factor: 8.262

3.  Relation of measures of asthma severity and response to treatment to outcome in acute severe asthma.

Authors:  C T Bolliger; P R Fourie; D Kotze; J R Joubert
Journal:  Thorax       Date:  1992-11       Impact factor: 9.139

4.  Modeling the impact of increased adherence to asthma therapy.

Authors:  Amory Schlender; Peter E Alperin; Helene L Grossman; E Rand Sutherland
Journal:  PLoS One       Date:  2012-12-07       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.